COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Study to Investigate the Effect of Food on Oral LBH589 Absorption in Patients With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00570284
Recruitment Status : Completed
First Posted : December 10, 2007
Last Update Posted : February 11, 2020
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
The primary purpose of this study is to evaluate the effect of food on oral LBH589 in adult patients with advanced solid tumors. This study will also evaluate the safety and efficacy of LBH589 in adult patients with advanced solid tumors

Condition or disease Intervention/treatment Phase
Cancer Drug: LBH589 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase Ib Open-label, Multicenter Cross-over Study to Investigate the Effect of Food on the Rate and Extent of Oral LBH589 Absorption in Patients With Advanced Solid Tumors
Study Start Date : November 2007
Actual Primary Completion Date : February 2011
Actual Study Completion Date : February 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: LBH589 Drug: LBH589
orally administered panobinostat at 20 mg twice weekly (core phase); orally administered panobinostat 45 mg twice weekly if 20 mg twice weekly was tolerated in Cycle 1 (extension phase)
Other Name: Panobinostat

Primary Outcome Measures :
  1. Levels of LBH589 in the blood [ Time Frame: every week for the first 3 weeks ]

Secondary Outcome Measures :
  1. Efficacy, Safety and tolerability [ Time Frame: throughout study to 28 days after last treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Patients with advanced solid tumors whose disease has progressed despite standard therapy or for whom no standard therapy exists
  • Age ≥ 18 years old
  • Patients must have adequate laboratory values
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
  • Ability to swallow capsules or tablets

Exclusion criteria:

  • Patients with active central nervous system (CNS) disease or brain metastases except those who have been previously treated and have been stable for at least 3 months.
  • Patients with a second primary malignancy that is currently clinically significant or requiring active intervention
  • Impaired heart function or clinically significant heart disease
  • Impairment of gastrointestinal (GI) function, or GI disease that may significantly alter the absorption of LBH589
  • Ongoing diarrhea
  • Liver or renal disease with impaired hepatic or renal functions
  • Concomitant use of any anti-cancer therapy or certain drugs
  • Female patients who are pregnant or breast feeding
  • Patients not willing to use an effective method of birth control

Other protocol-defined inclusion/exclusion criteria may apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00570284

Layout table for location information
United States, California
Novartis Investigative Site
Los Angeles, California, United States
United States, Connecticut
Novartis Investigative Site
Norwalk, Connecticut, United States
United States, Maryland
Novartis Investigative Site
Rockville, Maryland, United States
United States, Massachusetts
Novartis Investigative Site
Boston, Massachusetts, United States
United States, New Hampshire
Novartis Investigative Site
Lebanon, New Hampshire, United States
United States, New York
Novartis Investigative Site
New York, New York, United States
United States, Wisconsin
Novartis Investigative Site
Madison, Wisconsin, United States
Novartis Investigative Site
Stokholm, Sweden
Novartis Investigative Site
Zurich, Switzerland
Sponsors and Collaborators
Novartis Pharmaceuticals
Layout table for investigator information
Study Chair: Novartis Novartis
Additional Information:
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals Identifier: NCT00570284    
Other Study ID Numbers: CLBH589B2111
First Posted: December 10, 2007    Key Record Dates
Last Update Posted: February 11, 2020
Last Verified: August 2016
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
solid tumor
food effect
HDAC inhibitor
Additional relevant MeSH terms:
Layout table for MeSH terms
Antineoplastic Agents
Histone Deacetylase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action